Chemokine response to febrile urinary tract infection

Slides:



Advertisements
Similar presentations
Kamyar Kalantar-Zadeh  Kidney International 
Advertisements

Chemokine response to febrile urinary tract infection
Volume 61, Issue 1, Pages (January 2002)
Monocyte chemoattractant chemokines in cystic fibrosis
Propofol-related green urine
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative.
The urinary metabolome of chronic kidney disease
Reassessment of the care of the patient with chronic kidney disease
M. De Fost, W. Chierakul, R. Limpaiboon, A. Dondorp, N. J. White, T
Volume 58, Issue 1, Pages (July 2000)
Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real?  S. Andrulli, S. Di Filippo, F. Locatelli 
Kamyar Kalantar-Zadeh  Kidney International 
Volume 70, Pages S21-S25 (December 2006)
The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age  B.O. Eriksen, O.C. Ingebretsen  Kidney International 
Urinary tract infections revisited
Abnormalities in lipoprotein metabolism in hemodialysis patients
Methotrexate in the urine
Comorbidity and confounding in end-stage renal disease
Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load 
Proinflammatory effects of iron sucrose in chronic kidney disease
Volume 74, Issue 3, Pages (August 2008)
Volume 70, Issue 11, Pages (December 2006)
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Volume 54, Issue 5, Pages (November 1998)
Volume 76, Issue 3, Pages (August 2009)
The epidemiology of chronic kidney disease
Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott 
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease  S. Bianchi, R. Bigazzi, V.M. Campese 
Volume 68, Issue 1, Pages (July 2005)
Volume 70, Issue 12, Pages (December 2006)
Elke Wühl, Otto Mehls, Franz Schaefer  Kidney International 
Blood pressure targets in hemodialysis patients
Infected glomerulus Kidney International
Volume 76, Issue 6, Pages (September 2009)
A physician's perseverance uncovers problems in a key nephrology study
M.B. Kerrn, N. Frimodt-Møller, F. Espersen 
Extracorporeal therapy in sepsis: are we there yet?
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Proteinuria and hypertensive nephrosclerosis in African Americans
Volume 74, Issue 8, Pages (October 2008)
Alternate-day dialysis may be needed for hemodialysis patients
Volume 93, Issue 1, Pages (January 2018)
Nephrology Crossword: Glomerulonephritis
V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen 
Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis  N.-Y. Zalunardo, C.-L. Rose, I.W.Y.
Shannon D. Smith, Marcia A. Wheeler, Marc I. Lorber, Robert M. Weiss 
Urinary biomarkers in the early diagnosis of acute kidney injury
Kathy E. Sietsema, Antonino Amato, Sharon G. Adler, Eric P. Brass 
Phosphate binders on iron basis: A new perspective?
Organ transplantation goes to the movies
Cystinuria subtype and the risk of nephrolithiasis1
Volume 72, Issue 2, Pages (July 2007)
Treatment of the primary hyperoxalurias: A new chapter
Volume 74, Issue 7, Pages (October 2008)
Joshua P. Metlay, Daniel E. Singer  Clinical Microbiology and Infection 
Is complement a target for therapy in renal disease?
Volume 59, Issue 6, Pages (June 2001)
Volume 86, Issue 2, Pages (August 2014)
Volume 70, Issue 5, Pages (September 2006)
Volume 62, Issue 5, (November 2002)
Volume 72, Issue 11, Pages (December 2007)
Impact of antibiotic restrictions: the patient's perspective
Volume 70, Issue 10, Pages (November 2006)
The International Pediatric Peritonitis Registry: Starting to walk
Antioxidant therapy in hemodialysis patients: a systematic review
Volume 86, Issue 3, Pages (September 2014)
Volume 68, Issue 4, Pages (October 2005)
Presentation transcript:

Chemokine response to febrile urinary tract infection Gisela Otto, Marie Burdick, Robert Strieter, Gabriela Godaly  Kidney International  Volume 68, Issue 1, Pages 62-70 (July 2005) DOI: 10.1111/j.1523-1755.2005.00381.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Urine chemokine concentrations in 50 patients with febrile urinary tract infection. Samples were obtained at inclusion and during the first 24 hours after the onset of antibiotic therapy. The peak 24-hour values represent the highest concentrations in each patient during this period. Dots represent values from individual patients and the horizontal bars the median in each group. Chemokines are not usually detected in urine from uninfected and otherwise healthy individuals. Kidney International 2005 68, 62-70DOI: (10.1111/j.1523-1755.2005.00381.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Decline in urine chemokine concentrations after onset of therapy. Values are in percent of the concentration at inclusion and group means at 6 and 24 hours are shown. *P < 0.05; **P < 0.01; ***P < 0.001, Wilcoxon signed ranks test for paired data. CXCL1 (×), CXCL3 (*), CXCL5 (♦), CXCL8 CXCL9 (▴), CXCL10 (•), CCL2 (+), CCL4 and CCL5 (▪). Kidney International 2005 68, 62-70DOI: (10.1111/j.1523-1755.2005.00381.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Chemokine response and bacteremia. Chemokines that were higher in the bacteremic than in nonbacteremic patients at 12 hours after onset of therapy are shown (Mann-Whitney U test). *P < 0.05; **P < 0.01. Kidney International 2005 68, 62-70DOI: (10.1111/j.1523-1755.2005.00381.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Chemokine concentrations in relation to host background variables. (A) Complicating disease. (B) CXCL1 and CCL2 in relation to gender (Mann-Whitney U test). *P < 0.05; **P < 0.01. Kidney International 2005 68, 62-70DOI: (10.1111/j.1523-1755.2005.00381.x) Copyright © 2005 International Society of Nephrology Terms and Conditions